EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The onco-bariatric paradigm: a tri-phasic metabolic obesity framework for synergizing glucagon-like peptide-1 receptor agonists and metabolic bariatric surgery

Dong Jin Park, Yoonhong Kim, Dongjae Jeon, Young Suk Park, Kyung Won Seo, Ki Hyun Kim

Kosin Medical Journal · 31.03.2026 · 41 (1) · 3-8

DOI: 10.7180/kmj.26.154 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Kosin Medical Journal, erschienen am 31.03.2026. Verfasst von Dong Jin Park und 5 weiteren Autor:innen. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obesity is a chronic, progressive neuroendocrine disease that warrants a shift toward an “onco-bariatric” treatment paradigm. This study introduces the tri-phasic metabolic obesity (TPMO) framework, which integrates glucagon-like peptide-1 receptor agonists (GLP-1 RAs) with metabolic bariatric surgery (MBS). Recent clinical and economic evidence—including findings from the Indiana multicenter study and the Highmark Health analysis—was reviewed to evaluate the effectiveness of the TPMO model in improving surgical and metabolic outcomes. The TPMO framework streamlines the patient journey through three synergistic phases. In the neoadjuvant phase, a 4–8-week course of GLP-1 RAs reduces liver volume and visceral fat, thereby improving surgical access, provided that treatment is discontinued 1 week before surgery to mitigate aspiration risk. During the core surgery phase, MBS provides a definitive metabolic reset and remains the most cost-effective treatment, yielding an average savings of $11,689 per patient over 2 years compared with medication alone. In the adjuvant phase, pharmacotherapy—used by 17.2% of post-bariatric patients—counteracts metabolic adaptation and supports sustained weight loss, while a high-protein intake (≥1.2 g/kg/day) is essential for preserving lean body mass. The TPMO framework represents a precision-based, synergistic standard of care designed to promote durable, cost-effective long-term metabolic health within the onco-bariatric paradigm.

Zitieren

APA

Park, D. J., Kim, Y., Jeon, D., Park, Y. S., Seo, K. W., & Kim, K. H. (2026). The onco-bariatric paradigm: a tri-phasic metabolic obesity framework for synergizing glucagon-like peptide-1 receptor agonists and metabolic bariatric surgery. Kosin Medical Journal, 41(1), 3-8. https://doi.org/10.7180/kmj.26.154

Vancouver

Park DJ, Kim Y, Jeon D, Park YS, Seo KW, Kim KH. The onco-bariatric paradigm: a tri-phasic metabolic obesity framework for synergizing glucagon-like peptide-1 receptor agonists and metabolic bariatric surgery. Kosin Medical Journal. 2026;41(1):3-8. doi:10.7180/kmj.26.154

BibTeX
@article{Park2026,
  author = {Park, Dong Jin and Kim, Yoonhong and Jeon, Dongjae and Park, Young Suk and Seo, Kyung Won and Kim, Ki Hyun},
  title = {The onco-bariatric paradigm: a tri-phasic metabolic obesity framework for synergizing glucagon-like peptide-1 receptor agonists and metabolic bariatric surgery},
  journal = {Kosin Medical Journal},
  year = {2026},
  volume = {41},
  number = {1},
  pages = {3--8},
  doi = {10.7180/kmj.26.154}
}
Kostenlos starten →